^
Association details:
| Biomarker: | EGFR exon 18 deletion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + oleclumab (MEDI9447) (CD73 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
CT163 - CD73 inhibitor oleclumab plus osimertinib for advanced EGFRm NSCLC: First report of a Phase 1b/2 study
Published date:
03/10/2021
Excerpt:
This phase 1b/2, multi-center, dose escalation/expansion study (NCT03381274) evaluates the safety and efficacy of oleclumab plus osimertinib (osi) in locally advanced/metastatic EGFRm NSCLC....Pts had histologically or cytologically confirmed...TKI-sensitive EGFR mutation (exon 19 del, L858R)....Oleclumab + osi was well tolerated at RP2D. Compared to T790M-negative EGFRm NSCLC pts in a prior study of osi monotherapy, ORR was similar (21% vs 19%) but mPFS was longer (2.8 vs 11.0 mos).
Trial ID:
